Plus Therapeutics (PSTV) Liabilities and Shareholders Equity (2016 - 2025)
Plus Therapeutics has reported Liabilities and Shareholders Equity over the past 16 years, most recently at $16.3 million for Q4 2025.
- Quarterly Liabilities and Shareholders Equity rose 146.12% to $16.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $57.4 million through Dec 2025, up 88.55% year-over-year, with the annual reading at $16.3 million for FY2025, 146.12% up from the prior year.
- Liabilities and Shareholders Equity was $16.3 million for Q4 2025 at Plus Therapeutics, down from $18.7 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $24.8 million in Q3 2021 and troughed at $5.6 million in Q1 2024.
- The 5-year median for Liabilities and Shareholders Equity is $16.0 million (2023), against an average of $16.1 million.
- Year-over-year, Liabilities and Shareholders Equity crashed 64.06% in 2024 and then soared 167.56% in 2025.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $22.0 million in 2021, then increased by 8.58% to $23.9 million in 2022, then plummeted by 52.29% to $11.4 million in 2023, then crashed by 41.75% to $6.6 million in 2024, then soared by 146.12% to $16.3 million in 2025.
- Per Business Quant, the three most recent readings for PSTV's Liabilities and Shareholders Equity are $16.3 million (Q4 2025), $18.7 million (Q3 2025), and $10.4 million (Q2 2025).